TOP TEN perturbations for 39879_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39879_s_at
Selected probe(set): 224686_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39879_s_at (224686_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):2.3731718Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.2646933Number of Samples:4 / 2
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.1847763Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.1694841Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.1631508Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):2.0718098Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tissue (adult)
Relative Expression (log2-ratio):2.0270882Number of Samples:5 / 6
Experimental | myotonic dystrophy study 4 (skeletal muscle; DM1) |
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
Control | normal skeletal muscle tissue (adult) |
Commercially purchased normal adult skeletal muscle tissue samples. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.0112734Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.9578323Number of Samples:2 / 13
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)
Relative Expression (log2-ratio):-1.915329Number of Samples:22 / 11
Experimental | ovarian tumor study 11 (high grade) |
Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma. | |
Control | ovarian tumor study 11 (low grade) |
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. |
Organism: Homo sapiens
Gene: 39879_s_at
Selected probe(set): 232987_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39879_s_at (232987_at) across 6674 perturbations tested by GENEVESTIGATOR:
basal cell carcinoma study 2 / normal skin tissue
Relative Expression (log2-ratio):1.3593845Number of Samples:2 / 64
Experimental | basal cell carcinoma study 2 |
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC). | |
Control | normal skin tissue |
Normal skin samples from healthy donors. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-1.206501Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton's tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):-1.1471949Number of Samples:4 / 4
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton's tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton's tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
Langerhans cell histiocytosis study 3 / normal tonsillar T-lymphocyte sample
Relative Expression (log2-ratio):-1.1032248Number of Samples:10 / 4
Experimental | Langerhans cell histiocytosis study 3 |
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease). | |
Control | normal tonsillar T-lymphocyte sample |
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue. |
Merkel cell carcinoma study 3 (metastatic) / normal skin tissue
Relative Expression (log2-ratio):1.0943718Number of Samples:11 / 64
Experimental | Merkel cell carcinoma study 3 (metastatic) |
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin. | |
Control | normal skin tissue |
Normal skin samples from healthy donors. |
skin squamous cell carcinoma study 6 / normal skin tissue
Relative Expression (log2-ratio):1.081644Number of Samples:4 / 64
Experimental | skin squamous cell carcinoma study 6 |
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC). | |
Control | normal skin tissue |
Normal skin samples from healthy donors. |
memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)
Relative Expression (log2-ratio):-1.061861Number of Samples:6 / 6
Experimental | memory B cell study 1 (CD27high) |
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. | |
Control | memory B cell study 1 (undivided) |
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours. |
atopic dermatitis study 21 (non-lesional; dermis) / normal dermis tissue
Relative Expression (log2-ratio):1.0198059Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (non-lesional; dermis) |
Non-lesional dermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal dermis tissue |
Dermal samples isolated from healthy subjects by laser capture microdissection. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-0.9296255Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
alglucosidase alfa study 1 (week 52) / normal quadriceps tissue
Relative Expression (log2-ratio):-0.9220047Number of Samples:10 / 7
Experimental | alglucosidase alfa study 1 (week 52) |
Quadriceps muscle biopsy sample from patients with glycogen storage disease type II (Morbus Pomps, Pompe disease). Sample was taken 52 weeks after starting a 52 weeks lasting therapy with recombinant human cid alpha-glucosidase (rhGAA; Myozyme). ATC code: | |
Control | normal quadriceps tissue |
Quadriceps biopsy muscle samples from control subjects. |
Organism: Homo sapiens
Gene: 39879_s_at
Selected probe(set): 1555964_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39879_s_at (1555964_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):3.2072277Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):3.0369148Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; whole skin) |
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):3.0035038Number of Samples:3 / 4
Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):2.3949823Number of Samples:3 / 4
Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):-2.3691254Number of Samples:2 / 5
Experimental | colorectal cancer study 43 (metastase; brain) |
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
Control | colorectal cancer study 43 (metastase; lung) |
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
OPM-1 / MM1.S
Relative Expression (log2-ratio):2.0261154Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-1.6155882Number of Samples:3 / 3
Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):1.6054077Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):1.5564432Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):1.543026Number of Samples:2 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |